Lofton calls the Phase 3 retatrutide results she has seen impressive and notes the drug is drawing a lot of attention right now.
Recap by typeshit. Post by @drhollylofton on Instagram.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
The OCTANE study of 194 adults, presented at EASD 2026, found an average 4.1% drop over three months on oral semaglutide. Doctors call it early, unreviewed evidence.
She points out the only categorical A1C figure reported: 73.5% on CagriSema hit 6.5% or lower from a baseline of 8.0, versus 15.9% on placebo.
Loading…